FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101472517> ?p ?o ?g. }

• W2101472517 endingPage "1955" @default.
• W2101472517 startingPage "1948" @default.
• W2101472517 abstract "Performance status (PS) is a prognostic factor in patients with metastatic colorectal cancer. Clinical trials typically enroll less than 10% of patients with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain.Individual data from 6,286 patients (509 PS2 patients) from nine clinical trials were used to compare treatment efficacy by PS. Progression-free survival (PFS), grade > or = 3 adverse events, 60-day all-cause mortality, overall survival (OS), and response rate (RR) were explored in the full set of nine trials and in the five trials comparing first-line monotherapy with combination therapy.Compared with patients with PS of 0 or 1, PS2 patients had significantly higher rates of grade > or = 3 nausea (8.5% v 16.4%, respectively; P < .0001) and vomiting (7.6% v 11.9%, respectively; P = .006) and 60-day all-cause mortality (2.8% v 12.0%, respectively; P < .0001). PS2 was prognostic for PFS (hazard ratio [HR] = 1.52; P < .0001; median PFS, 7.6 months for PS 0 or 1 v 4.9 months for PS2), OS (HR = 2.18; P < .0001; median OS, 17.3 months for PS 0 or 1 v 8.5 months for PS2), and RR (odds ratio = 0.61; P < .0001; 43.8% for PS 0 or 1 v 32.0% for PS2). The relative benefit and toxicity of experimental versus control treatment and monotherapy versus combination therapy were not different in PS 0 or 1 patients versus PS2 patients.In clinical trials, PS2 patients derive similar benefit from superior treatment as patients with PS of 0 to 1 but with an increased risk of toxicities and 12% 60-day mortality. Although current treatment provides benefit, new approaches are required to approach 1-year median survival for PS2 patients." @default.
• W2101472517 created "2016-06-24" @default.
• W2101472517 creator A5002036484 @default.
• W2101472517 creator A5011642439 @default.
• W2101472517 creator A5012784092 @default.
• W2101472517 creator A5033411652 @default.
• W2101472517 creator A5043737761 @default.
• W2101472517 creator A5051645391 @default.
• W2101472517 creator A5054670872 @default.
• W2101472517 creator A5058562981 @default.
• W2101472517 creator A5060197466 @default.
• W2101472517 creator A5060306466 @default.
• W2101472517 creator A5066167770 @default.
• W2101472517 creator A5080788977 @default.
• W2101472517 creator A5081504508 @default.
• W2101472517 creator A5085949674 @default.
• W2101472517 date "2009-04-20" @default.
• W2101472517 modified "2023-10-18" @default.
• W2101472517 title "Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer" @default.
• W2101472517 cites W141482010 @default.
• W2101472517 cites W1969825132 @default.
• W2101472517 cites W2023385961 @default.
• W2101472517 cites W2044792687 @default.
• W2101472517 cites W2049564837 @default.
• W2101472517 cites W2059916220 @default.
• W2101472517 cites W2102601598 @default.
• W2101472517 cites W2109498035 @default.
• W2101472517 cites W2118971132 @default.
• W2101472517 cites W2121368761 @default.
• W2101472517 cites W2128403792 @default.
• W2101472517 cites W2128447158 @default.
• W2101472517 cites W2132545630 @default.
• W2101472517 cites W2133399075 @default.
• W2101472517 cites W2136055188 @default.
• W2101472517 cites W2137242191 @default.
• W2101472517 cites W2150273386 @default.
• W2101472517 cites W2156575195 @default.
• W2101472517 cites W2157769714 @default.
• W2101472517 cites W2162315065 @default.
• W2101472517 cites W2166112130 @default.
• W2101472517 cites W2314927739 @default.
• W2101472517 cites W4238267829 @default.
• W2101472517 cites W4366064733 @default.
• W2101472517 doi "https://doi.org/10.1200/jco.2008.20.2879" @default.
• W2101472517 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2669760" @default.
• W2101472517 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19255311" @default.
• W2101472517 hasPublicationYear "2009" @default.
• W2101472517 type Work @default.
• W2101472517 sameAs 2101472517 @default.
• W2101472517 citedByCount "154" @default.
• W2101472517 countsByYear W21014725172012 @default.
• W2101472517 countsByYear W21014725172013 @default.
• W2101472517 countsByYear W21014725172014 @default.
• W2101472517 countsByYear W21014725172015 @default.
• W2101472517 countsByYear W21014725172016 @default.
• W2101472517 countsByYear W21014725172017 @default.
• W2101472517 countsByYear W21014725172018 @default.
• W2101472517 countsByYear W21014725172019 @default.
• W2101472517 countsByYear W21014725172020 @default.
• W2101472517 countsByYear W21014725172021 @default.
• W2101472517 countsByYear W21014725172022 @default.
• W2101472517 countsByYear W21014725172023 @default.
• W2101472517 crossrefType "journal-article" @default.
• W2101472517 hasAuthorship W2101472517A5002036484 @default.
• W2101472517 hasAuthorship W2101472517A5011642439 @default.
• W2101472517 hasAuthorship W2101472517A5012784092 @default.
• W2101472517 hasAuthorship W2101472517A5033411652 @default.
• W2101472517 hasAuthorship W2101472517A5043737761 @default.
• W2101472517 hasAuthorship W2101472517A5051645391 @default.
• W2101472517 hasAuthorship W2101472517A5054670872 @default.
• W2101472517 hasAuthorship W2101472517A5058562981 @default.
• W2101472517 hasAuthorship W2101472517A5060197466 @default.
• W2101472517 hasAuthorship W2101472517A5060306466 @default.
• W2101472517 hasAuthorship W2101472517A5066167770 @default.
• W2101472517 hasAuthorship W2101472517A5080788977 @default.
• W2101472517 hasAuthorship W2101472517A5081504508 @default.
• W2101472517 hasAuthorship W2101472517A5085949674 @default.
• W2101472517 hasBestOaLocation W21014725172 @default.
• W2101472517 hasConcept C121608353 @default.
• W2101472517 hasConcept C126322002 @default.
• W2101472517 hasConcept C141071460 @default.
• W2101472517 hasConcept C143998085 @default.
• W2101472517 hasConcept C156957248 @default.
• W2101472517 hasConcept C197934379 @default.
• W2101472517 hasConcept C207103383 @default.
• W2101472517 hasConcept C2776694085 @default.
• W2101472517 hasConcept C2776907518 @default.
• W2101472517 hasConcept C2780580376 @default.
• W2101472517 hasConcept C2780852908 @default.
• W2101472517 hasConcept C44249647 @default.
• W2101472517 hasConcept C526805850 @default.
• W2101472517 hasConcept C535046627 @default.
• W2101472517 hasConcept C71924100 @default.
• W2101472517 hasConcept C90924648 @default.
• W2101472517 hasConceptScore W2101472517C121608353 @default.
• W2101472517 hasConceptScore W2101472517C126322002 @default.
• W2101472517 hasConceptScore W2101472517C141071460 @default.
• W2101472517 hasConceptScore W2101472517C143998085 @default.

• next